Skip to main
  1. Stocks
  2. Serina Therapeutics, Inc.
  3. Forecast
SER

SER Stock Forecast & Price Target

SER Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Serina Therapeutics is viewed favorably because its POZ platform has already shown near zero-order release in SER-214, supporting the core thesis that it can smooth drug exposure, lower peak-driven toxicity, and preserve efficacy across payloads. The lead asset, SER-252, targets a large and underserved advanced Parkinson’s disease market, with early blinded Cohort 1 data showing sustained PK and improvement in motor function in 8 randomized patients (6 active, 2 placebo) without meaningful safety concerns, while the company’s grant revenue is still modest relative to the platform’s upside. With FDA alignment on a 505(b)(2) pathway, first patient-in in Q1 2026, and key readouts expected around YE26 through 1H27, the stock’s appeal rests on a de-risked mechanism, a validated clinical setup, and meaningful platform expansion potential.

Bears say

Serina Therapeutics is a clinical-stage biotechnology company with no approved products, a limited operating history, and significant operating losses since inception, which makes its reliance on future capital raises a key fundamental weakness. The near-term outlook is especially fragile because SER-252 still faces an upcoming P1b readout, where any unexpected safety signal would be a major negative, while even a lack of efficacy would leave the program vulnerable in an intensely competitive Parkinson’s disease landscape. Although the clinical hold has been lifted, the earlier regulatory disruption, ongoing uncertainty around the formulation, and commercialization hurdles such as pricing, reimbursement, and slow primary-care adoption all reinforce a high-risk, execution-dependent story.

SER has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

SER Analyst Forecast & Price Prediction

Get the latest SER stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SER

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Serina Therapeutics, Inc. (SER) Forecast

Analysts have given SER a Strong Buy based on their latest research and market trends.

According to 1 analysts, SER has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Serina Therapeutics, Inc. (SER)


SER Analyst Forecast & Price Prediction

Get the latest SER stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SER

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SER stock data and trends